REFERENCES
- American Society of Hematology. 2019. American Society of Hematology to launch sickle cell disease clinical trials network. https://www.hematology.org/Newsroom/Press-Releases/2018/8952.aspx (accessed November 6).
- FDA. 2019. Guidance for clinical investigators, sponsors, and IRBs. Investigational new drug applications (INDs) – determining whether human research studies can be conducted without an IND. https://www.fda.gov/media/79386/download (accessed November 7).
- Kodish, E. 2003. Pediatric ethics and early-phase childhood cancer research: Conflicted goals and the prospect of benefit. Accountability in Research 10(1): 17–25.
- Kodish, E., J. Lantos, C. Stocking, P. A. Singer, M. Siegler, and F. L. Johnson. 1991. Bone marrow transplantation for sickle cell disease – A study of parents’ decisions. New England Journal of Medicine 325(19): 1349–1353.
- Meier, E. R., J. V. Dioguardi, and N. Kamani. 2015. Current attitudes of parents and patients toward hematopoietic stem cell transplantation. Pediatric Blood and Cancer 62(7): 1277–1284.
- Miller, P. B., and C. Weijer. 2005. Evaluating benefits and harms in research on healthy children. In Ethics and research with children: A case-based approach, ed. Eric Kodish, 29–45. New York: Oxford University Press.
- Samson, A., E. Tomiak, J. Dimillo, et al. 2009. The lived experience of hope among parents of a child with Duchenne muscular dystrophy: Perceiving the human being beyond illness. Chronic Illness 5(2): 103–114.
- U.S. Department of Health and Human Services. 1983. 45CFR46. Subpart D. Additional protections for children involved as subjects in research. Federal Registrar 48: 9818.
- Unguru, Y. 2015. Ethical challenges in early-phase pediatric research for life-limiting illness. Seminars in Pediatric Neurology 22(3): 177–186.
- van Besien, K., M. Koshy, L. Anderson-Shaw, et al. 2001. Allogenic stem cell transplantation for sickle cell disease: A study of patients’ decisions. Bone Marrow Transplantation 28(6): 545–549.